A detailed history of First Trust Advisors LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 12,283 shares of VKTX stock, worth $645,962. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,283
Holding current value
$645,962
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $612,184 - $865,583
12,283 New
12,283 $777,000
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $8,805 - $13,144
-4,173 Reduced 3.9%
102,755 $297,000
Q1 2022

May 13, 2022

SELL
$3.0 - $4.88 $18,066 - $29,387
-6,022 Reduced 5.33%
106,928 $321,000
Q4 2021

Feb 08, 2022

BUY
$4.6 - $6.72 $64,464 - $94,174
14,014 Added 14.16%
112,950 $520,000
Q3 2021

Nov 15, 2021

BUY
$5.58 - $7.04 $552,062 - $696,509
98,936 New
98,936 $621,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.